Base to Base biotech podcast 19: Nipro on dialysis and LenioBio on cell-free protein synthesis

This week’s podcast is sponsored by Nipro.

This week, our conversations are with Jesus Garcia, Nipro Product Manager Water Treatment, on Nipro ’s recently-launched product LiniXia, a reverse osmosis (RO) system that ensures safe and pure water for every dialysis session, and on the future of biologics manufacturing with cell-free protein synthesis with LenioBio CEO André Goerke.

Interview times:

05:16 Nipro

15:52 LenioBio

NIPRO

Nipro Medical Europe is part of Nipro Corporation Japan, a leading global healthcare company established in 1954. With over 40.000 employees worldwide, Nipro serves the Medical Device, Pharmaceutical, and Pharmaceutical Packaging industries.

Nipro Medical Europe is a global market leader offering a comprehensive portfolio of medical disposables and machines across six divisions: Renal, Hospital Products, Diabetes, Cardiopulmonary, Enzymes, and In Vitro Diagnostics.

With a worldwide footprint of manufacturing sites, sales offices, and distribution centres, NIPRO Medical Europe services the EMEA region. From hospitals to home care, Nipro provides products that improve the lives of patients and meet the needs of healthcare professionals and procurement managers alike.

Nipro recently launched LiniXia, its new Reverse Osmosis (RO) system that reliably ensures safe and pure water for every dialysis session.

With LiniXia, Nipro has added an entire range of water treatment solutions to its renal care portfolio, combining innovative RO technology with user-friendly controls, detailed logs, and remote supervision capabilities, all while ensuring up to 90% yield of high quality ultra-pure water.

Visit http://www.nipro-group.com/renal-care for more information.

Our conversation is with Jesus Garcia, Nipro Product Manager Water Treatment.

LenioBio

LenioBio GmbH is a life sciences biotech company dedicated to transforming protein production through its proprietary ALiCE technology.

By eliminating the limitations and bottlenecks of traditional cell-based systems, LenioBio empowers researchers to explore new frontiers in protein expression and accelerate the development of cutting-edge therapeutics and diagnostics.

ALiCE was launched earlier this year. It is the first eukaryotic cell-free expression platform specifically engineered for rapid antibody discovery and screening. By offering an end-to-end service covering DNA template generation, lead generation, purification and analysis, this new solution slashes production timelines from four weeks to as little as three days.

We had a conversation on ALiCE and the future of biologics manufacturing with cell-free protein synthesis with LenioBio CEO André Goerke.

To get in touch with guest suggestions, or to sponsor or advertise on the podcast, please email [e-mail]